JOHN MARAGANORE

CIK 1180432 · Chief Executive Officer · last filed 2026-07-06

JOHN MARAGANORE is a Chief Executive Officer who has filed 122 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for TAK, was dated Jul 6, 2026. Across all open-market trades the lifetime net is −$121.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $60.2M across reported positions. 90 SEC filings were submitted jointly with ALNYLAM PHARMACEUTICALS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$60.15M

Companies

10

Total Filings

122

Lifetime Open-Market Net

-$121.06M

Filer Profile

Reported Address
75 SIDNEY ST
CAMBRIDGE, MA 02139
Related Filers
ALNYLAM PHARMACEUTICALS, INC. — 90 joint filings, latest 2021-12-23
bluebird bio, Inc. — 11 joint filings, latest 2017-09-18
Beam Therapeutics Inc. — 7 joint filings, latest 2026-06-05
MILLENNIUM PHARMACEUTICALS INC — 2 joint filings, latest 2002-11-18
TAKEDA PHARMACEUTICAL CO LTD — 2 joint filings, latest 2026-07-06
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TAK Director 13,800 $18.26 $252.0K $0 1 2026-07-06
KYMR Director $114.96 $0 5 2026-06-25
RAPP Director $43.62 $0 2 2026-06-10
BEAM Director $23.99 $0 6 2026-06-05
COAG Director 35,948 $39.40 $1.42M $0 1 2026-05-04
PROK Director $1.80 $0 1 2023-07-03
AGIO Director 30,028 $33.60 $1.01M -$1.80M 18 2022-06-23
ALNY Chief Executive Officer 231,115 $248.68 $57.47M -$114.58M 77 2021-12-23
bluebird bio, Inc. (BLUE) Delisted Director 1,236 $4.97 $6.1K -$4.68M 9 2017-09-18
Regulus Therapeutics Inc. (RGLS) Delisted Director 51,254 $8.16 $418.2K $0 1 2012-10-11

Recent Filings

122 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-06 TAK Mixed +3,800 $0 EDGAR
2026-06-25 KYMR Grant (A) $0 EDGAR
2026-06-10 RAPP Grant (A) $0 EDGAR
2026-06-05 BEAM Grant (A) $0 EDGAR
2026-05-04 COAG Mixed +35,948 $0 EDGAR
2025-06-26 KYMR Grant (A) $0 EDGAR
2025-06-18 RAPP Grant (A) $0 EDGAR
2025-06-06 BEAM Grant (A) $0 EDGAR
2024-06-20 KYMR Grant (A) $0 EDGAR
2024-06-07 BEAM Grant (A) $0 EDGAR
Showing 110 of 122
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.